This episode of The Motley Fool's Market Checkup is dedicated to the world's largest pure-play biotech stock, Gilead Sciences (GILD 0.23%). Market Checkup gives a full examination of Gilead's second-quarter results, takes a closer look at the company's current product portfolio, and analyzes the future drugs that have investors excited about the stock's future.
In this video, health-care analysts David Williamson and Max Macaluso drill down on Gilead's strong drug development pipeline. Watch and find out what makes pending hepatitis-C drug candidate sofosbuvir both so exciting and potentially dangerous for Gilead investors.
Sofosbuvir is a nucleotide inhibitor, and the only member of its hep-C drug class to make it through clinical trials without major safety issues. However, if a problem reared its head once the drug were on sale, it could have a devastating effect on Gilead shares. Watch David and Max discuss this "what-if" scenario in the video.
